LOGO
LOGO

Quick Facts

STADA And Bio-Thera Receive European Commission's Marketing Approval For Gotenfia

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Friday, STADA, a global specialty, generic and consumer healthcare medicines company, and Bio-Thera Solutions, a commercial-stage biopharmaceutical company, have received marketing authorization from the European Commission for their Gotenfia (golimumab) biosimilar referencing Simponi.

The marketing authorization for Gotenfia for several chronic inflammatory autoimmune diseases follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) in December 2025.

Shengfeng Li, CEO of Bio-Thera Solutions, commented, "Building on our prior approvals and launches in the US and EU, this European authorization further establishes Bio-Thera as a major global biosimilar developer and manufacturer."

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19